Login to get immediate access to this content.
LoginSpeaker: Matthew Goetz, USA
#ESMO23: Breaking Science in Breast Cancer Video Series
Expert Report on Outcomes of CDK4/6 inhibitors in the Adjuvant Treatment of HR-positive, HER2-negative Early Breast Cancer
Abstracts discussed:
- LBA17 - Adjuvant abemaciclib plus endocrine therapy for high-risk, HR+, HER2-, early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcome, presented by Nadia Harbeck
- 240MO - Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC), presented by Matthew P. Goetz
- LBA23 - Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + endocrine therapy (ET) in patients (pts) with HR+/HER2_ early breast cancer (EBC), presented by Aditya Bardia
Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.
The study results covered, and speakers in this video series, have been selected exclusively by ESMO.
Published on 27 Oct 2023
